Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Virtual Coverage of the 34th Annual Roth Conference
March 9, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction using world-class technology and drug development infrastructure. Mydecine was founded in 2020 to address a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Participation Schedule for March Investor Conferences
March 3, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that it will be attending three investor conferences in March. The upcoming events include the 34th Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference and Maxim Group’s Virtual Growth Conference. […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Positive Pre-IND Meeting with FDA for Smoking Cessation Study
March 1, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced a positive meeting with the Food and Drug Administration (“FDA”) regarding the company’s Investigational New Drug (“IND”) and breakthrough therapy status applications. During the meeting, Mydecine reviewed its IND application to administer […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005
February 28, 2022
Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005 This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Addresses Its ‘A to Z’ Approach to Drug Development in New Video
February 24, 2022
Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has released a video discussing the company’s fully integrated approach to drug development. “At Mydecine, we have a strong drug development pipeline where we really look at finding compounds with incredible […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Communicating the Therapeutic Benefits of Psychedelics; Advocating for Accurate and Consistent Messaging to Promote The Acceptance of Psychedelics in Therapeutics
February 23, 2022
Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing a vital role in pushing the knowledge of the benefits of psychedelic compounds […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs
February 16, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development
February 15, 2022
Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails […]
Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience
February 15, 2022
Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans
February 8, 2022
Mydecine has summitted a pre-IND briefing package to the FDA in readiness for its phase 2/3 smoking cessation trial scheduled for Q2 2022 The study will be led by Dr. Matthew Johnson, with the placebo-controlled research being conducted at Johns Hopkins University Mydecine also announced its partnership with Combat Stress to use psilocybin in a […]
InvestorNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program
February 8, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale
February 3, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses
February 2, 2022
Canadian-based mental health treatment-focused biotechnology company Mydecine Innovations Group has been advancing research on the use and improvement of compounds found in nature, particularly the psychedelic psilocybin compound Mydecine recently announced an LOI with The Newly Institute to use Mydecine’s psilocybin and MDMA for treatment at The Newly’s mental health clinics nationwide The LOI is […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation
February 1, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market
January 31, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans
January 24, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress and the King’s College London to utilize psilocybin as part of a psychoactive-assisted psychotherapy treatment for post-traumatic stress disorder (“PTSD”) in veterans. According to […]
Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices
January 24, 2022
Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support […]
Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast
January 19, 2022
Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies
January 18, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada. The […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy
January 13, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast
January 11, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the […]
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Josh Bartch, CEO of Mydecine Innovations Group Inc.
January 11, 2022
NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) — via InvestorWire — IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program
January 10, 2022
The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program
January 10, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, has announced its engagement of JBN Partners LLC to increase public awareness of and interest in the company, its management and its products. Under the collaboration, JBN will coordinate certain investor […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care
January 7, 2022
Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’
January 6, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in a recent episode of “Gamechangers LIVE.” The podcast series shines a spotlight on individuals who are gamechangers in their fields and shares perspective on their journeys, mindsets, struggles […]
IBN (InvestorBrandNetwork) Announces Gamechangers LIVE Interview with Mydecine Innovations Group Inc. CEO Joshua Bartch
January 6, 2022
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted financial news and publishing company for private and public entities, today announces that Joshua Bartch, Co-Founder, Chairman and CEO of Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation
January 5, 2022
Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds
December 30, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company, has aimed to transform the treatment of mental health disorders and addiction since its inception. The company has already developed first- and second-generation novel therapeutics designed to treat addiction, post-traumatic stress disorder (“PTSD”) and other mental health conditions. “Mydecine recently released its third-quarter 2021 […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform
December 22, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with Maya. The two companies plan to co-develop a novel digital therapeutics (DTx) platform, which would allow Mydecine to enhance treatment effectiveness by […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine
December 20, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment
December 20, 2021
Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Advancing MYCO-001 to Bring Safer, More Effective Smoking Cessation Treatment to Market
December 17, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today published a blog article discussing positive clinical data assessing psilocybin for smoking cessation and its upcoming clinical trials. The piece, titled “Why We’re Bullish on MYCO-001, 99% Psilocybin, to Treat […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin
December 10, 2021
The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones
December 9, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into an agreement with an investor to complete a non-brokered private placement (the “financing”) of a convertible secured subordinated debenture in the principal amount of C$5.5 million. […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year
December 7, 2021
2021 marked Mydecine’s patent application for its MYCO-003 drug candidate It also marked notable clinical trials on various aspects, including smoking cessation Mydecine also got into a 5-year research agreement with JHU for clinical research on the use of psychedelics for therapeutics These milestones have laid down the groundwork, not just for Q3 of the […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs
December 6, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has filed a full patent application covering multiple families of psilocin analogs. According to the update, the application includes solutions to directly address further precision in delivery control […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment
December 1, 2021
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement
December 1, 2021
Mydecine’s recent Q3 update includes the company’s five-year research agreement with Johns Hopkins University School of Medicine, which will cover clinical research related to the therapeutic use of psychedelics Mydecine has also filed for various patents on proprietary compounds within the company’s IP portfolio In addition, an updated version of the company’s virtual health platform, […]
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Excited for Seamless Phase 2/3 Clinical Research as Dr. Matthew Johnson Presents Interim Results of Current Smoking Cessation Study at the Psychedelic Medicine Business Event: Wonderland
November 22, 2021
Dr. Matthew Johnson discussed psilocybin for tobacco smoking cessation at this year’s Psychedelic Medicine Business Event: Wonderland, in Miami He shared preliminary findings from his recent study on substance use disorder, along with the participants’ feedback on their experience Dr. Johnson, along with Mydecine, are set to embark on their clinical study utilizing MYCO-001 for […]